Nuvectis Pharma reports $39 mln cash, Phase 1a trial success, Phase 1b imminent.

• NXP900 completes Phase 1a study in solid tumors and drug-drug interaction study in healthy volunteers. • Initiation of Phase 1b program imminent. • Strengthened cash position after July ATM shares acquisition. • June 30, 2025 proforma cash position: approximately $39 million. • Nuvectis Pharma reports Q2 2025 financial results and business progress.

Nuvectis Pharma (NASDAQ: NVCT) reported significant advancements in its clinical pipeline and financial position during the second quarter of 2025. The company announced the successful completion of the NXP900 Phase 1a dose escalation study in advanced solid tumors and a drug-drug interaction study in healthy volunteers. These milestones position NXP900 as the primary focus for the company, with the Phase 1b program set to begin imminently.

The financial results for Q2 2025 revealed a net loss of $6.3 million, compared to $4.4 million in Q2 2024, reflecting increased R&D expenses. However, the company's cash position was significantly strengthened following an ATM share acquisition by a healthcare-focused institutional investor in July. As of June 30, 2025, Nuvectis reported a proforma cash balance of approximately $39 million, providing operational stability through the second half of 2027.

Nuvectis Pharma's Chairman and CEO, Ron Bentsur, commented on the company's progress, stating, "We have had a series of important events that we believe put the company in an excellent position for growth. We announced the successful completions of the NXP900 Phase 1a dose escalation study and the NXP900 drug-drug interaction study, both strongly supporting the initiation of the NXP900 Phase 1b program. On the financial side, we strengthened our cash position following the acquisition of shares by a healthcare-focused institutional investor through our ATM facility."

The company's increased R&D expenses reflect the investment in completing the NXP900 DDI study, while higher G&A expenses include non-cash stock-based compensation. Despite widening losses, Nuvectis has extended its cash runway, reducing near-term dilution risk and allowing management to focus on clinical execution.

Nuvectis Pharma continues to explore the potential of NXP800 in endometrial and prostate cancers while deprioritizing its development to focus resources on NXP900. The company's financial and clinical progress positions it well to deliver on its ambitious plan for NXP900.

References:
[1] https://www.stocktitan.net/news/NVCT/nuvectis-pharma-inc-reports-second-quarter-2025-financial-results-4bk1doxztsih.html
[2] https://www.globenewswire.com/fr/news-release/2025/07/31/3124897/0/en/Nuvectis-Pharma-Provides-Final-Clinical-Data-Update-from-the-NXP800-Phase-1b-Study-in-Ovarian-Cancer-and-Reports-Completion-of-the-NXP900-Phase-1a-Dose-Escalation-Study.html